Neuphoria Therapeutics Inc Financials
Neuphoria Therapeutics Inc (NEUP) reported $15.6M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 revenue arrival turned a long cash-burn model into near break-even operations without a major cost reset.
From FY2024 to FY2025, operating loss narrowed from-$17.9M to-$1.1M even though R&D and SG&A were roughly flat, which implies the improvement came mainly from new revenue absorbing an existing expense base rather than from austerity. That reading is reinforced by operating cash flow swinging from-$14.7M to$77K , so the near break-even result was not just an accounting artifact.
The balance sheet still looks equity-funded rather than debt-driven:
FY2025 reads as a transition year, not a fully self-financing steady state: retained earnings were still
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Neuphoria Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Neuphoria Therapeutics Inc has an operating margin of -7.2%, meaning the company loses $7 on every $100 of revenue. This results in a profitability score of 26/100.
Not available for Neuphoria Therapeutics Inc, and counted as zero in the overall score.
Neuphoria Therapeutics Inc has a moderate D/E ratio of 0.50. This balance of debt and equity financing earns a leverage score of 60/100.
With a current ratio of 3.56, Neuphoria Therapeutics Inc holds $3.56 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.
Not available for Neuphoria Therapeutics Inc, and counted as zero in the overall score.
Neuphoria Therapeutics Inc posts a -2.1% return on equity (ROE), meaning it loses $2 for every $100 of shareholders' equity. This results in a returns score of 27/100. This is up from -88.6% the prior year.
Neuphoria Therapeutics Inc scores -6.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($21.1M) relative to total liabilities ($9.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Neuphoria Therapeutics Inc passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Neuphoria Therapeutics Inc reported a net loss of $400K while generating $77K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Neuphoria Therapeutics Inc generated $15.6M in revenue in fiscal year 2025.
Neuphoria Therapeutics Inc's EBITDA was -$466K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 97.3% from the prior year.
Neuphoria Therapeutics Inc reported -$400K in net income in fiscal year 2025. This represents an increase of 97.4% from the prior year.
Neuphoria Therapeutics Inc earned -$0.23 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Neuphoria Therapeutics Inc held $14.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Neuphoria Therapeutics Inc's operating margin was -7.2% in fiscal year 2025, reflecting core business profitability.
Neuphoria Therapeutics Inc's net profit margin was -2.6% in fiscal year 2025, showing the share of revenue converted to profit.
Neuphoria Therapeutics Inc's ROE was -2.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 86.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Neuphoria Therapeutics Inc invested $9.0M in research and development in fiscal year 2025. This represents a decrease of 4.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NEUP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | N/A | $15.6M | N/A | N/A |
| R&D Expenses | N/A | $9.0M-4.4% | $9.4M-28.0% | $13.1M |
| SG&A Expenses | N/A | $7.8M-8.3% | $8.5M-4.9% | $8.9M |
| Operating Income | N/A | -$1.1M+93.7% | -$17.9M+18.6% | -$22.0M |
| Income Tax | N/A | -$468K-436.4% | -$87K+37.3% | -$139K |
| Net Income | N/A | -$400K+97.4% | -$15.5M+27.5% | -$21.4M |
| EPS (Diluted) | — | -$0.23 | -$18.62 | -$0.02 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NEUP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $28.6M+3.4% | $27.6M-3.2% | $28.6M |
| Current Assets | $15.0M+14.0% | $13.2M-1.0% | $13.3M |
| Cash & Equivalents | $14.2M+12.7% | $12.6M+4.2% | $12.1M |
| Accounts Receivable | $12K-90.6% | $127K-70.2% | $426K |
| Goodwill | $8.6M-0.6% | $8.7M0.0% | $8.7M |
| Total Liabilities | $9.6M-5.6% | $10.2M+55.0% | $6.6M |
| Current Liabilities | $4.2M+10.2% | $3.8M+39.8% | $2.7M |
| Total Equity | $19.0M+8.6% | $17.5M-20.5% | $22.0M |
| Retained Earnings | -$178.3M-0.2% | -$178.0M-9.5% | -$162.5M |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
NEUP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$17.2M | $77K+100.5% | -$14.7M-0.3% | -$14.6M |
| Financing Cash Flow | $18.6M | $1.5M-89.9% | $15.1M+291.6% | $3.9M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NEUP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Operating Margin | -7.2% | N/A | N/A |
| Net Margin | -2.6% | N/A | N/A |
| Return on Equity | -2.1%+86.5pp | -88.6%+8.6pp | -97.1% |
| Return on Assets | -1.4%+54.6pp | -56.0%+18.8pp | -74.9% |
| Current Ratio | 3.56+0.1x | 3.45-1.4x | 4.87 |
| Debt-to-Equity | 0.50-0.1x | 0.58+0.3x | 0.30 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Similar Companies
Where Neuphoria Therapeutics Inc Ranks
Frequently Asked Questions
What is Neuphoria Therapeutics Inc's annual revenue?
Neuphoria Therapeutics Inc (NEUP) reported $15.6M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Neuphoria Therapeutics Inc profitable?
No, Neuphoria Therapeutics Inc (NEUP) reported a net income of -$400K in fiscal year 2025, with a net profit margin of -2.6%.
What is Neuphoria Therapeutics Inc's EBITDA?
Neuphoria Therapeutics Inc (NEUP) had EBITDA of -$466K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Neuphoria Therapeutics Inc's operating margin?
Neuphoria Therapeutics Inc (NEUP) had an operating margin of -7.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Neuphoria Therapeutics Inc's net profit margin?
Neuphoria Therapeutics Inc (NEUP) had a net profit margin of -2.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Neuphoria Therapeutics Inc's return on equity (ROE)?
Neuphoria Therapeutics Inc (NEUP) has a return on equity of -2.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Neuphoria Therapeutics Inc's operating cash flow?
Neuphoria Therapeutics Inc (NEUP) generated $77K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Neuphoria Therapeutics Inc's total assets?
Neuphoria Therapeutics Inc (NEUP) had $28.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Neuphoria Therapeutics Inc spend on research and development?
Neuphoria Therapeutics Inc (NEUP) invested $9.0M in research and development during fiscal year 2025.
What is Neuphoria Therapeutics Inc's current ratio?
Neuphoria Therapeutics Inc (NEUP) had a current ratio of 3.56 as of fiscal year 2025, which is generally considered healthy.
What is Neuphoria Therapeutics Inc's debt-to-equity ratio?
Neuphoria Therapeutics Inc (NEUP) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neuphoria Therapeutics Inc's return on assets (ROA)?
Neuphoria Therapeutics Inc (NEUP) had a return on assets of -1.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Neuphoria Therapeutics Inc's Altman Z-Score?
Neuphoria Therapeutics Inc (NEUP) has an Altman Z-Score of -6.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Neuphoria Therapeutics Inc's Piotroski F-Score?
Neuphoria Therapeutics Inc (NEUP) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neuphoria Therapeutics Inc's earnings high quality?
Neuphoria Therapeutics Inc (NEUP) reported a net loss of $400K while generating $77K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Neuphoria Therapeutics Inc?
Neuphoria Therapeutics Inc (NEUP) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.